Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute

References

• Brussee JM, Calvier EA, Krekels EH, et al. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. Expert Rev Clin Pharmacol. 2016;9(9):1235–1244.
   Google Scholar
• Allegaert K, Mian P, van den Anker JN. Developmental pharmacokinetics in neonates: maturational changes and beyond. Curr Pharm Des. 2017;23(38):5769–5778.
   Google Scholar
• Hoppu K, Anabwani G, Garcia-Bournissen F, et al. The status of paediatric medicines initiatives around the world—what has happened and what has not? Eur J Clin Pharmacol. 2012;68(1):1–10.
   Google Scholar
• Ward RM, Benjamin D, Barrett JS, et al. Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates. Pediatr Res. 2017;81(5):692–711.
   Google Scholar
• Allegaert K, Smits A, van den Anker JN. Drug evaluation studies in neonates: how to overcome the current limitations. Expert Rev Clin Pharmacol. 2018;11(4):387–396.
   Google Scholar
• Michelet R, Bocxlaer JV, Vermeulen A. PBPK in preterm and term neonates: a review. Curr Pharm Des. 2017;23(38):5943–5954.
   Google Scholar
• Yellepeddi V, Rower J, Liu X, et al. State-of-the-art review on physiologically based pharmacokinetic modeling in pediatric drug development. Clin Pharmacokinet. 2018. DOI:10.1007/s40262-018-0677-y.
   Google Scholar
• Maharaj AR, Edginton AN. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. CPT Pharmacometrics Syst Pharmacol. 2014;3(11):1–13.
   Google Scholar
• Himebauch AS, Zuppa A. Methods for pharmacokinetic analysis in young children. Expert Opin Drug Metab Toxicol. 2014;10(4):497–509.
   Google Scholar
• Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘bottom-up’ vs ‘top-down’ recognition of covariates. Drug Metab Pharmacokinet. 2009;24(1):53–75.
   Google Scholar
• Upton RN, Foster DJ, Abuhelwa AY. An introduction to physiologically-based pharmacokinetic models. Paediatr Anaesth. 2016;26(11):1036–1046.
   Google Scholar
• Leong R, Vieira ML, Zhao P, et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012;91(5):926–931.
   Google Scholar
• Zhao P. Report form the EMA workshop on qualification and reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):71–72.
   Google Scholar
• European Medicines Agency. [cited 2018 Jul 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211315.pdf
   Google Scholar
• Wagner C, Zhao P, Pan Y, et al. Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK. CPT Pharmacometrics Syst Pharmacol. 2015;4(4):226–230.
   Google Scholar
• Li M, Zhao P, Pan Y, et al. Predictive performance of physiologically based pharmacokinetics models for the effect of food on oral drug absorption: current status. CPT Pharmacometrics Syst Pharmacol. 2018;7(2):82–89.
   Google Scholar
• Lin L, Wong H. Predicting oral absorption: mini-review on physiologically-based pharmacokinetic models. Pharmaceutics. 2017;9(4):E41.
   Google Scholar
• Yu G, Zheng QS, Li GF. Similarities and differences in gastrointestinal physiology between neonates and adults: a physiologically based pharmacokinetic modeling perspective. Aaps J. 2014;16(6):112–1166.
   Google Scholar
• Johnson TN, Bonner JJ, Tucker GT, et al. Development and applications of a physiologically-based model of paediatric oral drug absorption. Eur J Pharm Sci. 2018;115:57–67.
   Google Scholar
• Somani AA, Thelen K, Zheng S, et al. Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds. Br J Clin Pharmacol. 2016;81(1):137–147.
   Google Scholar
• Khalil F, Laer S. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as s model drug. Aaps J. 2014;16(2):226–239.
   Google Scholar
• Staelens S, van Den Driessche M, Barclay D, et al. Gastric emptying in healthy newborns fed an intact protein formula, a partially and an extensively hydrolysed formula. Clin Nutr. 2008;27(2):264–268.
   Google Scholar
• Leuven KU. [cited 2018 Jul 18]. Available from: https://gbiomed.kuleuven.be/english/research/50000715/50000716/ungap
   Google Scholar
• Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci. 2010;99(3):1107–1122.
   Google Scholar
• Van Den Abeele J, Rayyan M, Hoffman I, et al. Gastric fluid composition in a paediatric population: age-dependent changes relevant for gastrointestinal drug disposition. Eur J Pharm Sci. 2018. DOI:10.1016/j.ejps.2018.07.022.
   Google Scholar
• Smits A, De Cock RF, Allegaert K, et al. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob Agents Chemother. 2015;59(10):6344–6351.
   Google Scholar
• Ghersi-Egea JF, Saudrais E, Strazielle N. Barriers to drug distribution into the perinatal and postnatal brain. Pharm Res. 2018;35(4):84.
   Google Scholar
• Smits A, Kulo A, van den Anker J, et al. The amikacin research program: a stepwise approach to validate dosing regimens in neonates. Expert Opin Drug Metab Toxicol. 2017;13(2):157–166.
   Google Scholar
• Sethi PK, White CA, Cummings BS, et al. Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin. Pediatr Res. 2016;79(3):409–415.
   Google Scholar
• Smits A, Pauwels S, Oyaert M, et al. Factors impacting unbound vancomycin concentrations in neonates and young infants. Eur J Clin Microbiol Infect Dis. 2018;37(8):1503–1510.
   Google Scholar
• Smits A, Kulo A, Verbesselt R, et al. Cefazolin plasma protein binding and its covariates in neonates. Eur J Clin Microbiol Infect Dis. 2012;31(12):3359–3365.
   Google Scholar
• Nau H, Luck W, Kuhnz W. Decreased serum protein binding of diazepam and its major metabolite in the neonate during the postnatal week relate to increased free fatty acid levels. Br J Clin Pharmacol. 1984;17(1):92–98.
   Google Scholar
• Notariemi LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet. 1990;18(1):20–36.
   Google Scholar
• Malik P, Edginton A. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opin Drug Metab Toxicol. 2018;14(6):585–599.
   Google Scholar
• Maharaj AR, Gonzalez D, Cohen-Wolkowiez M, et al. Improving pediatric protein binding estimates: an evaluation of α1-acid glycoprotein maturation in healthy and infected subjects. Clin Pharmacokinet. 2018;57(5):577–589.
   Google Scholar
• Yang F, Tong X, McCarver DG, et al. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn. 2006;3(4):485–518.
   Google Scholar
• Lingvall M, Reith D, Broadbent R. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol. 2005;59(1):54–61.
   Google Scholar
• T’jollyn H, Vermeulen A, Van Bocxlaer J, et al. A physiologically based pharmacokinetic perspective on the clinical utility of albumin-based dose adjustments in critically ill patients. Clin Pharmacokinet. 2018;57(1):59–69.
   Google Scholar
• Smits A, De Cock P. Antibiotic PK/PD research in critically ill neonates and children: how do we proceed? Int J Pharmacokinet. 2018;3(1):1–3.
   Google Scholar
• Dalhoff A. Seventy-five years of research on protein binding. Antimicrob Agents Chemother. 2018;62(2):e01663–17.
   Google Scholar
• Hines RN. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm. 2013;452:3–7.
   Google Scholar
• Abduljalil K, Jamei M, Rostami-Hodjegan A, et al. Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model. Aaps J. 2014;16(3):568–576.
   Google Scholar
• Van Donge T, Mian P, Tibboel D, et al. Drug metabolism in early infancy: opioids as an illustration. Expert Opin Drug Metab Toxicol. 2018;14(3):287–301.
   Google Scholar
• Jiang XL, Zhao P, Barrett JS, et al. Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst Pharmacol. 2013;2:e80.
   Google Scholar
• Claassen K, Thelen K, Coboeken K, et al. Development of a physiologically-based pharmacokinetic model for preterm neonates: evaluation with in vivo data. Curr Pharm Des. 2015;21(39):5688–5698.
   Google Scholar
• T’jollyn H, Snoeys J, Vermeulen A, et al. Physiologically based pharmacokinetic predictions of tramadol exposure throughout pediatric life: an analysis of the different clearance contributors with emphasis on CYP2D6 maturation. Aaps J. 2015;17(6):1376–1387.
   Google Scholar
• Emoto C, Johnson TN, Neuhoff S, et al. PBPK model of morphine incorporating developmental changes in hepatic OCT1 and UGT2B7 proteins to explain the variability in clearances in neonates and small infants. CPT Pharmacometrics Syst Pharmacol. 2018;7(7):464-473.
   Google Scholar
• Zhou W, Johnson TN, Bui KH, et al. Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther. 2018;104(1):188–200.
   Google Scholar
• De Cock RF, Allegaert K, Schreuder MF, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51(2):105–117.
   Google Scholar
• Allegaert K, Rayyan M, Anderson BJ. Impact of ibuprofen administration on renal drug clearance in the first weeks of life. Methods Find Exp Clin Pharmacol. 2006;28(8):519–522.
   Google Scholar
• Cristea S, Smits A, Kulo A, et al. Amikacin pharmacokinetics to optimize dosing in neonates with perinatal asphyxia treated with hypothermia. Antimicrob Agents Chemother. 2017;22(12):e01282–17.
   Google Scholar
• Dhont E, van der Heggen T, De Jaeger A, et al. Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients? Pediatr Nephrol. 2018. DOI:10.1007/s00467-018-4120-2.
   Google Scholar
• Liu X, Smits A, Wang Y, et al. Impact of disease on amikacin pharmacokinetics and dosing in children. Ther Drug Monit. 2018. DOI:10.1097/FTD.0000000000000568.
   Google Scholar
• De Cock RF, Allegaert K, Sherwin CM, et al. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res. 2014;31(3):754–767.
   Google Scholar
• Bijleveld YA, de Haan TR, van der Lee JH, et al. Evaluation of a system-specific function to describe the pharmacokinetics of benzylpenicillin in term neonates undergoing moderate hypothermia. Antimicrob Agents Chemother. 2018;62(4):e02311–17.
   Google Scholar
• Björkman S. Prediction of drug disposition of infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol. 2005;59(6):691–704.
   Google Scholar
• Lukacova V, Goelzer P, Reddy M, et al. A physiologically based pharmacokinetic model for ganciclovir and its prodrug valganciclovir in adults and children. Aaps J. 2016;18(6):1453–1463.
   Google Scholar
• DeWoskin RS, Thompson CM. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul Toxicol Pharmacol. 2008;51(1):66–86.
   Google Scholar
• Rhodin MM, Anderson BJ, Peters AM. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67–76.
   Google Scholar
• De Gregori S, De Gregori M, Ranzani GN, et al. Drug transporters and renal drug disposition in the newborn. J Matern Fetal Neonatal Med. 2009;22(3):31–37.
   Google Scholar
• Brouwer KL, Aleksunes LM, Brandys B, et al. Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group. Clin Pharmacol Ther. 2015;98(3):266–287.
   Google Scholar
• Duan P, Fisher JW, Yoshida K, et al. Physiologically based pharmacokinetic prediction of linezolid and emtricitabine in neonates and infants. Clin Pharmacokinet. 2017;56(4):383–394.
   Google Scholar
• Zhou W, Johnson TN, Xu H, et al. Predictive performance of physiologically based pharmacokinetic and population pharmacokinetic modeling of renally cleared drugs in children. CPT Pharmacometrics Syst Pharmacol. 2016;5(9):475–483.
   Google Scholar
• Kimko H, Lee K. Improving realism in clinical trial simulations via real-world data. CPT Pharmacometrics Syst Pharmacol. 2017;6(11):727–729.
   Google Scholar
• Wilbaux M, Kasser S, Gromann J, et al. Personalized weight change prediction in the first week of life. Clin Nutr. 2018. DOI:10.1016/j.clnu.2018.04.001.
   Google Scholar
• Troutman JA, Sullivan MC, Carr GJ, et al. Development of growth equations from longitudinal studies of body weight and height in the full term and preterm neonate: from birth to four years postnatal age. Birth Defects Res. 2018;110(11):916–932.
   Google Scholar
• Raaijmakers A, Jacobs L, Rayyan M, et al. Catch-up growth in the first two years of life in extremely low birth weight (ELBW) infants is associated with lower body fat in young adolescence. PLoS One. 2017;12(3):e0173349.
   Google Scholar
• Raaijmakers A, Zhang ZY, Levtchenko E, et al. Ibuprofen exposure in early neonatal life does not affect renal function in young adolescence. Arch Dis Child Fetal Neonatal Ed. 2018;103(2):F107–F111.
   Google Scholar
• Raaijmakers A, Zhang ZY, Claessens J, et al. Does extremely low birth weight predispose to low-renin hypertension? Hypertension. 2017;69(3):443–449.
   Google Scholar
• Li GF, Zheng QS. Modeling drug disposition and drug-drug interactions through hypothesis-driven physiologically based pharmacokinetics: a reversal translation perspective. Eur J Drug Metab Pharmacokinet. 2018;43(3):369–371.
   Google Scholar
• Johnson TN, Jamei M, Rowland-Yeo K. How does in vivo biliary elimination of drugs change with age? Evidence from in vitro and clinical data using a systems pharmacology approach. Drug Metab Dispos. 2016;44(7):1090–1098.
   Google Scholar
• Donovan MD, Abduljalil K, Cryan JF, et al. Application of a physiologically-based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate. Biopharm Drug Dispos. 2018;39(3):125–134.
   Google Scholar
• Van Groen BD, van de Steeg E, Mooij MG, et al. Proteomics of human liver membrane transporters: a focus on fetuses and newborn infants. Eur J Pharm Sci. 2018;124:217–227.
   Google Scholar
• Hochwald O, Jabr M, Osiovich H, et al. Preferential cephalic redistribution of left ventricular cardiac output during therapeutic hypothermia for perinatal hypoxic-ischemic encephalopathy. J Pediatr. 2014;164(5):999–1004.e1.
   Google Scholar
• de Haan TR, Bijleveld YA, van der Lee JH, et al. Pharmacokinetics and pharmacodynamcis of medication in asphyxiated newborns during controlled hypothermia. The PharmaCool multicenter study. BMC Pediatr. 2012;12:45.
   Google Scholar
• Cristea S, Smits A, Kulo A, et al. Amikacin pharmacokinetics to optimize dosing in neonates with perinatal asphyxia treated with hypothermia. Antimicrob Agents Chemother. 2017;61(12):e01282–17.
   Google Scholar
• Rasool MF, Khalil F, Läer S. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. Clin Pharmacokinet. 2015;54(9):943–962.
   Google Scholar
• GitHub, Inc. [cited 2018 Jul 18]. Available from: https://github.com/open-systems-pharmacology
   Google Scholar
• ILSI Health and Environmental Sciences Institute. [cited 2018 Nov 13]. Available from: http://ilsi.org/hesi//wp-content/uploads/sites/11/2015/11/Neonatal-final.pptx
   Google Scholar
• Niederalt C, Kuepfer L, Solodenko J, et al. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. J Pharmacokinet Pharmacodyn. 2018;45(2):235–257.
   Google Scholar
• Dallmann A, Pfister M, van den Anker J, et al. Physiologically based pharmacokinetic modeling in pregnancy: a systematic review of published models. Clin Pharmacol Ther. 2018. DOI:10.1002/cpt.1084.
   Google Scholar
• Wei FF, Raaijmakers A, Zhang ZY, et al. Association between cognition and the retinal microvasculature in 11-year old children born preterm or at term. Early Hum Dev. 2018;118:1–7.
   Google Scholar
• Bertagnolli M, Xie LF, Paquette K, et al. Endothelial colony-forming cells in young adults born preterm: a novel link between neonatal complications and adult risks for cardiovascular disease. J Am Heart Assoc. 2018;7(14):e009720.
   Google Scholar
• Hellstrom A, Ley D, Hallberg B, et al. IGF-1 as a drug for preterm infants: a step-wise clinical development. Curr Pharm Des. 2017;23(38):5964–5970.
   Google Scholar
• El-Masri H, Kleinstreuer N, Hines RN, et al. Integration of life-stage physiologically based pharmacokinetic models with adverse outcome pathways and environmental exposure models to screen to environmental hazards. Toxicol Sci. 2016;152(1):230–243.
   Google Scholar
• Kirman CR, Suh M, Proctor DM, et al. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol. 2017;325:9–17.
   Google Scholar
• Baker T, Datta P, Rewers-Felkings K, et al. Transfer of inhaled cannabis into human breast milk. Obstet Gynecol. 2018;131(5):783–788.
   Google Scholar
• Delaney SR, Malik PRV, Stefan C, et al. Predicting escitalopram exposure to breastfeeding infants: integrating analytical and in silico techniques. Clin Pharmacokinet. 2018.
   Google Scholar
• Smits A, Annaert P, Allegaert K. Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology. Int J Pharm. 2013;452(1–2):8–13.
   Google Scholar
• Allegaert K, Smits A, van den Anker JN. Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician’s request for a more integrated approach. J Biomed Biotechnol. 2012;2012:103763.
   Google Scholar
• De Cock RF, Allegaert K, Brussee JM, et al. Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res. 2014;31(10):2643–2654.
   Google Scholar
• De Cock RF, Smits A, Allegaert K, et al. Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. J Antimicrob Chemother. 2014;69(5):1330–1338.
   Google Scholar